Growth Metrics

Summit Therapeutics (SMMT) Change in Account Payables (2019 - 2025)

Summit Therapeutics' Change in Account Payables history spans 7 years, with the latest figure at -$2.1 million for Q4 2025.

  • For Q4 2025, Change in Account Payables fell 240.29% year-over-year to -$2.1 million; the TTM value through Dec 2025 reached $15.3 million, up 659.45%, while the annual FY2025 figure was $15.3 million, 659.45% up from the prior year.
  • Change in Account Payables reached -$2.1 million in Q4 2025 per SMMT's latest filing, down from -$839000.0 in the prior quarter.
  • In the past five years, Change in Account Payables ranged from a high of $17.9 million in Q2 2025 to a low of -$3.5 million in Q2 2022.
  • Average Change in Account Payables over 5 years is $686900.0, with a median of -$426500.0 recorded in 2023.
  • The largest YoY upside for Change in Account Payables was 1102.6% in 2024 against a maximum downside of 1122.56% in 2024.
  • A 5-year view of Change in Account Payables shows it stood at -$1.4 million in 2021, then plummeted by 73.68% to -$2.4 million in 2022, then surged by 71.63% to -$672000.0 in 2023, then soared by 327.53% to $1.5 million in 2024, then crashed by 240.29% to -$2.1 million in 2025.
  • Per Business Quant, the three most recent readings for SMMT's Change in Account Payables are -$2.1 million (Q4 2025), -$839000.0 (Q3 2025), and $17.9 million (Q2 2025).